结直肠癌术中应用雷替曲塞腹腔灌注化疗的安全性研究

doi:10.3760/cma.j.issn.1673-422X.2016.06.005

摘要/Abstract

摘要： 目的探讨结直肠癌术中应用雷替曲塞腹腔灌注化疗的安全性。方法将60例行结直肠癌手术患者按照随机数字表法分为试验组（30例）和对照组（30例）。试验组采用手术＋术中雷替曲塞腹腔灌注化疗，对照组采用手术＋术中生理盐水腹腔灌注治疗。评价两组患者血常规、肝肾功能的变化情况以及术后不良反应、并发症的发生率。结果试验组手术前后白细胞分别为（6.36±2.63）×109/L、（8.20±2.08）×109/L，差异有统计学意义（t=3.06，P＜0.05）；中性粒细胞比例分别为65.17%±10.36%、72.21%±10.53%，差异有统计学意义（t=3.22，P＜0.05）；血小板分别为（261.03±84.74）×109/L、（228.47±58.69）×109/L，差异有统计学意义（t=2.07，P＜0.05）。试验组术后白细胞、中性粒细胞比例、血小板与对照组相比，差异均无统计学意义（均P>0.05）。试验组1～2级恶心（60.00%∶23.33%；χ2=8.30，P<0.05）和呕吐（30.00%∶6.67%；χ2=5.46，P<0.05）的发生率明显高于对照组。其他不良反应的发生率两组比较差异均无统计学意义（均P>0.05）。与对照组比较，试验组肠梗阻（6.67%∶3.33%，χ2=0.35，P>0.05）、切口感染（10.00%∶6.67%，χ2=0.22，P>0.05）、腹腔出血（0∶0）、吻合口瘘（3.33%∶0，P>0.05）发生率差异均无统计学意义。结论结直肠癌术中使用雷替曲塞进行腹腔灌注化疗，不良反应可耐受，不增加术后并发症，治疗过程安全可行。

关键词: 结直肠肿瘤, 雷替曲塞, 腹腔, 药物疗法

Abstract: Objective To investigate the intraoperative intraperitoneal chemotherapy security with raltitrexed in advanced colorectal cancer surgical operation. MethodsSixty patients with colorectal cancer undergone surgery were randomly divided into trial group (n=30) and control group (n=30) according to the random number table method. The trial group was given surgical operation plus with intraperitoneal chemotherapy with raltitrexed. The control group was given surgical operation plus with intraperitoneal saline perfusion. Theroutine blood test, liver and kidney functions, toxic side effects and complications in two groups before and after surgery were investigated. ResultsThe white blood cells in trial group before and after surgery was (6.36±2.63)×109/L vs. (8.20±2.08)×109/L, with statistically significant difference (t=3.06, P＜0.05). The ratio of absolute neutrophil count in trial group before and after surgery was 65.17%±10.36% vs.72.21%±10.53% (t=3.22, P＜0.05).The platelets in trial group before and after surgery was (261.03±84.74)×109/L vs.(228.47±58.69)×109/L (t=2.07, P＜0.05). The white blood cells, the ratio of absolute neutrophil count and the platelets after surgery had no statistically significant differences between the two groups (P>0.05). The trial group had higher 1, 2 level vomiting (60.00% vs. 23.33%; χ2=8.30, P<0.05), and nausea (30.00% vs. 6.67%; χ2=5.46, P<0.05) incidence rates, but there was no statistically significant difference in other toxic side effects (P>0.05). The major complications post operation included intestinal obstruction, incision infection, abdominal cavity bleeding, and anastomotic fistula. There were equivalent complications in two groups (6.67% vs. 3.33%, χ2=0.35, P>0.05; 10.00% vs. 6.67%, χ2=0.22, P>0.05; 0 vs. 0；3.33% vs. 0, P>0.05). ConclusionFor patients with advanced colorectal cancer, intraoperative intraperitoneal chemotherapy with raltitrexed is safe and feasible, and the adverse reactions can be tolerated without increasing postoperative complications.

Key words: Colorectal neoplasms, Raltitrexed, Abdominal cavity, Drug therapy

李舒媛，张庆怀，耿树安，高浩，杨景文. 结直肠癌术中应用雷替曲塞腹腔灌注化疗的安全性研究[J]. 国际肿瘤学杂志, 2016, 43(6): 420-423.

Li Shuyuan, Zhang Qinghuai, Geng Shu′an, Gao Hao, Yang Jingwen. Safty research of intraoperative intraperitoneal chemotherapy with raltitrexed for advanced colorectal cancer[J]. Journal of International Oncology, 2016, 43(6): 420-423.

参考文献

［1］ Thomassen I, van Gestel YR, Lemmens VE, et al. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin［J］. Dis Colon Rectum, 2013, 56(12): 1373-1380. ［2］陈建林, 宋卫蜂, 陈栋晖. 雷替曲寨治疗晚期大肠癌临床疗效的Mcta分析［J］. 中国新药与临床杂志, 2010, 29(11): 853-857. ［3］ Wang L, Wu Y, Lin L, et al. Metastasisassociated in colon cancer1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion［J］. Int J Cancer, 2013, 133(6): 1419-1430. DOI: 10.1002/ijc.28140. ［4］ Hagner N, Joerger M. Cancer chemotherapy: targeting folic acid synthesis［J］. Cancer Manag Res, 2010, 2: 293-301. DOI: 10.2147/CMR.S10043. ［5］ Jarmua A. Antifolate inhibitors of thymidylate synthase as anticancer drugs ［J］. Mini Rev Med Chem, 2010, 10(13): 1211-1222. ［6］ Votanopoulos KI, Swett K, Blackham AU, et al. Cytoreductivesurgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer［J］. Ann Surg Oncol, 2013, 20(4): 1088-1092. DOI: 10.1245/s10434-012-2787-3. ［7］ Elias D, El Otmany A, Bonnay M, et al. Human pharmacokinetic study of heated intraperitonealoxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis［J］. Oncology, 2002, 63(4): 346-352. ［8］曾良玉, 刘运山, 龚晓松, 等. 腹腔化疗预防结直肠癌术后肝转移及局部复发的临床观察［J］. 中国肿瘤临床与康复, 2004, 11(1): 74-75. DOI: 10.3969/j.issn.1005-8664.2004.01.033. ［9］ Cavaliere F, De Simone M, Virzì S, et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O.［J］. Eur J Surg Oncol, 2011, 37(2): 148-154. DOI: 10.1016/j.ejso.2010.10.014. ［10］姜海毅, 丁红光, 田晓卫, 等. 术中氟尿嘧啶植入剂腹腔化疗在局部进展期胃癌中的应用［J］. 中华肿瘤防治杂志, 2012, 19(15): 1166-1168. ［11］ Tanner EJ, Black DR, Zivanovic O, et al. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage ⅢC ovariancancer［J］. Gynecol Oncol, 2012, 124(1): 59-62. DOI: 10.1016/j.ygyno.2011.09.011. ［12］ Ceelen W,De Somer F, Van Nieuwenhove Y, et al. Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion(HIPEC) with oxaliplatin［J］. Eur J Surg Oncol, 2013, 39(7): 754-759. DOI: 10.1016/j.ejso.2012.07.120. ［13］ Hompes D, D′Hoore A, Van Cutsem E, et al. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal preoperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase Ⅱ clinical study［J］. Ann Surg Oncol, 2012, 19(7): 2186-2194. ［14］ Tsavaris N, Kosmas C, Vadiaka M, et al. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study［J］. Invest New Drugs, 2002, 20(1): 133-136. DOI: 10.1023/A:1014494503230. ［15］ Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation［J］. Health Technol Assess, 2008, 12(15): iii-iix, xi-162. ［16］ Cocconi G, Cunningham D, Van Cutsem E, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus highdose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group［J］. J ClinOncol, 1998, 16(9): 2943-2952. ［17］ Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study［J］. Anticancer Drugs, 2010, 21(6): 656-661. DOI: 10.1097/CAD.0b013e328337d469. ［18］覃金莲, 陆永奎, 刘莎, 等. 雷替曲塞对比5氟尿嘧啶一线治疗晚期结直肠癌疗效和不良反应的Meta分析［J］. 中国现代医学杂志, 2013, 23(14): 84-90.

[1]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[4]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[5]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[6]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[7]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[8]	李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.
[9]	陈卓, 陶俊, 陈琳, 柯晶. 外周血miR-194联合粪便miR-143检测对结直肠癌临床筛查的价值[J]. 国际肿瘤学杂志, 2023, 50(5): 268-273.
[10]	黄镇, 张蔡羽天, 柯少波, 石薇, 赵文思, 陈永顺. 结直肠癌患者术后预后模型的构建[J]. 国际肿瘤学杂志, 2023, 50(3): 157-163.
[11]	徐良富, 李袁飞. MSS型结直肠癌肿瘤微环境及免疫联合治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(3): 186-190.
[12]	刘玉杰, 赵志强, 王子琤. 早期结直肠癌患者外周血单个核细胞中TOP2A、ERBB2的水平及其诊断价值[J]. 国际肿瘤学杂志, 2023, 50(12): 717-722.
[13]	耿睿, 马俊强, 郭强, 牛钊峰. 老年乳腺癌患者的综合治疗方式选择倾向及其影响因素[J]. 国际肿瘤学杂志, 2023, 50(11): 650-654.
[14]	陶红, 殷红, 罗宏, 陶佳瑜. 靶向肿瘤相关巨噬细胞增强结直肠癌免疫检查点抑制剂疗效的潜在策略[J]. 国际肿瘤学杂志, 2023, 50(11): 683-687.
[15]	王熙, 吴川清. 结直肠癌多药耐药逆转的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 42-46.